Cprx stock forecast.

CPRX - Free Report) is scheduled to report its first-quarter 2023 results on May 10, 2023. Catalyst Pharmaceuticals’ earnings surprise history has been mixed so far. The company’s earnings ...Catalyst Pharmaceuticals (CPRX) Stock Forecast & Price Target $14.06 +0.20 (+1.44%) (As of 11/24/2023 ET) Compare Today's Range $13.81 $14.09 50-Day Range $11.69 …Catalyst Pharmaceuticals last posted its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The firm had revenue of $102.69 million for the quarter, compared to analyst estimates of $100.17 million.For Catalyst Pharmaceuticals stock forecast for 2023, 1 predictions are offered for each month of 2023 with average Catalyst Pharmaceuticals stock forecast of $13.76, a high forecast of $13.76, and a low forecast of $13.76. The average Catalyst Pharmaceuticals stock forecast 2023 represents a 0.34% increase from the last price of $13.710000038147.

In the last 12 months, CPRX had revenue of $348.39 million and earned $62.04 million in profits. Earnings per share was $0.53. Revenue. 348.39M. Gross Profit. 301.04M. Operating Income. 75.92M. Pretax Income.

Find out why CPRX stock is a Hold. ... During Catalyst's Q4, 2022 earnings call (the "Call") CEO McEnany forecast its 2023 revenues in a $245-$255 million range.

Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business Every investor in Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) should be aware of the most ...Check price target & stock forecast for Catalyst here>>> While the ABR calls for buying Catalyst, it may not be wise to make an investment decision solely based on this information.TSE Stock 12 Months Forecast. $11.60. (70.59% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Trinseo in the last 3 months. The average price target is $11.60 with a high forecast of $23.00 and a low forecast of $7.00. The average price target represents a 70.59% change from the last price of $6.80.Click here to find out why CPRX stock is rated as a buy. ... which adds further confidence towards achieving our FYCOMPA full year 2023 net product revenue forecast of $130 million. Adding FYCOMPA ...... stock price performance. 48. Table of Contents. Market Information. Our common stock trades on the Nasdaq Capital Market under the symbol “CPRX.” The closing ...

Catalyst Pharma (CPRX) will release its next earnings report on Mar 13, 2024. In the last quarter Catalyst Pharma reported -$0.3 EPS in relation to -$0.29 expected by the market.

The 5 analysts offering 1 year price forecasts for CPRX have a max estimate of — and a min estimate of —. Analyst rating Based on 5 analysts giving stock ratings to CPRX in the past 3 months.

Is Catalyst Pharmaceuticals (NASDAQ:CPRX) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...For the current quarter, Catalyst is expected to post earnings of $0.21 per share, indicating a change of +133.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over ...View Catalyst Pharmaceuticals, Inc CPRX investment & stock information. Get the latest Catalyst Pharmaceuticals, Inc CPRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.The stock, however, lost 2.1% during the after-market hours on Thursday. CPRX reported earnings of 33 cents per share for the second quarter of 2023, beating the Zacks Consensus Estimate of 25 cents.Catalyst Pharma (CPRX) is an absolute monster. Not only is the company posting huge sales and earnings growth in a sector that rarely has either, the stock has more than doubled over the last few months. There are 801 stocks in the biotech group tracked by Investors Business Daily, and CPRX ranks at the very top (see image in chart).Find the latest Catalyst Pharmaceuticals, Inc. (CPRX) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Catalyst is expected to post earnings of $0.20 ...Based on short-term price targets offered by five analysts, the average price target for Catalyst Pharmaceutical comes to $23.30. The forecasts range from a low of $15.50 to a high of $27.00. The ...CPRX Stock 12 Months Forecast. $23.30. (81.32% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high forecast of $27.00 and a low forecast of $15.50. The average price target represents a 81.32% change from the last price of $12.85.Stock Price Forecast. The 8 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 55.00 and a low estimate of 20.00 ...According to our current CPRX stock forecast, the value of Catalyst Pharmaceuticals shares will drop by -8.79% and reach $ 12.82 per share by December 5, 2023. According to our technical indicators, the current sentiment is Bullish while the Fear & Greed Index is showing 39 (Fear).Based on short-term price targets offered by five analysts, the average price target for Catalyst Pharmaceutical comes to $23.30. The forecasts range from a low of $15.50 to a high of $27.00. The ...Find the latest Catalyst Pharmaceuticals, Inc. (CPRX) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance

Nov 10, 2023 · Analyst Future Growth Forecasts. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next ...

View Catalyst Pharmaceuticals, Inc CPRX investment & stock information. Get the latest Catalyst Pharmaceuticals, Inc CPRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Read more to see why CPRX stock is a Strong Buy. Skip to content. Explore Alpha Picks; Subscribe to Premium; ... the company forecasts a non-GAAP full-year 2023 net income of between $195 million ...For Catalyst Pharmaceuticals stock forecast for 2023, 1 predictions are offered for each month of 2023 with average Catalyst Pharmaceuticals stock forecast of $13.76, a high forecast of $13.76, and a low forecast of $13.76. The average Catalyst Pharmaceuticals stock forecast 2023 represents a 0.34% increase from the last price of $13.710000038147. Brokerage Recommendation Trends for CPRX. Check price target & stock forecast for Catalyst here>>> While the ABR calls for buying Catalyst, it may not be wise to make an investment decision solely ...Price target. 23.30R USD +9.11 +64.20%. The 5 analysts offering 1 year price forecasts for Catalyst Pharmaceuticals, Inc. have a max estimate of 27.00 and a min estimate of 15.50.Catalyst Pharmaceuticals Inc is a biopharmaceutical company with a market cap of $1.37 billion. It focuses on developing and commercializing innovative therapies for people with rare, debilitating ...Catalyst Pharmaceuticals, Inc. (CPRX) share price prediction for 2023, 2024, 2025, 2026 and 2027. CPRX one year forecast. Catalyst Pharmaceuticals stock monthly and ...Dec 4, 2023 · Furthermore, the stock’s position above its 200-day simple moving average is also a positive sign. When a stock is trading above this average, it indicates a bullish trend and suggests that the stock’s price is likely to continue rising. The $0.11 increase in CPRX shares since the previous market close demonstrates a positive price change.

Track Catalyst Pharmaceuticals Inc (CPRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Dec 1, 2023 · https://www.catalystpharma.com. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of ...

CRSP Stock 12 Months Forecast. Based on 16 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $85.25 with a high forecast of $220.00 and a low forecast of $42.00. The average price target represents a 21.84% change from the last price of $69.97.7 brokerages have issued 12-month price targets for Cross Country Healthcare's shares. Their CCRN share price targets range from $21.00 to $40.00. On average, they anticipate the company's share price to reach $27.50 in the next year. This suggests a possible upside of 34.7% from the stock's current price.Nov 10, 2023 · Analyst Future Growth Forecasts. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next ... The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. Learn more on CPRX's analyst rating history. Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors? Analysts like Catalyst Pharmaceuticals more than other Medical companies.29 mar 2021 ... | $CPRX Stock Analysis. 7.3K views · 2 years ago AKRON ...more. Everything Money. 203K ... | Paypal fair value Price! Road To Retiring•629 views.Catalyst Pharma (CPRX) will release its next earnings report on Mar 13, 2024. In the last quarter Catalyst Pharma reported -$0.3 EPS in relation to -$0.29 expected by the market.Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Catalyst is expected to post earnings of $0.22 ...Find the latest Catalyst Pharmaceuticals, Inc. (CPRX) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceIs Catalyst Pharmaceuticals (NASDAQ:CPRX) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...

Aug 23, 2022 · 1. Catalyst Pharmaceuticals. Catalyst Pharmaceuticals ( CPRX 1.44%) is crushing Tesla stock because it's in the process of cornering a rare disease market that'll be worth hundreds of millions of ... Find the latest Compugen Ltd. (CGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Catalyst is expected to post earnings of $0.22 ...Instagram:https://instagram. 5 year bond yieldbest investment bankerswhat stock apps allow day tradingtop oil etfs Shares of CPRX were one of the market’s most successful stock stories in 2022. That’s because they delivered investors a year-to-date gain of over 136% (through Dec. 16). And while it’s true ... surgetrader reviewspne In 2024, MMAT is forecast to generate $18,194,381,920 in revenue, with the lowest revenue forecast at $18,194,381,920 and the highest revenue forecast at $18,194,381,920. If you're new to stock investing, here's how to buy Meta Materials stock .Catalyst Pharmaceuticals trounced Wall Street's third-quarter forecasts and raised its full-year outlook, giving CPRX stock a boost on Thursday.. X. The company makes Firdapse, a treatment for ... byd vs tesla The stock, however, lost 2.1% during the after-market hours on Thursday. CPRX reported earnings of 33 cents per share for the second quarter of 2023, beating the Zacks Consensus Estimate of 25 cents.Jan 8, 2023 · Shares of CPRX were one of the market’s most successful stock stories in 2022. That’s because they delivered investors a year-to-date gain of over 136% (through Dec. 16). And while it’s true ... View the latest Catalyst Pharmaceuticals Inc. (CPRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.